Table 1. Patients characteristic.
| Whole Study Group (n = 5826) |
No PTSD (n = 5076) |
PTSD (n = 750) |
p-value* | |
|---|---|---|---|---|
| Gender (male) | 5619 | 4896 | 723 | .916 |
| Age (years) | 59.4 ± 11.5 | 60.1 ± 11.6 | 54.9 ± 11.5 | <.001 |
| Follow-up (years) | 9.6 ± 5.6 | 10.1 ± 5.6 | 6.1 ± 5.0 | <.001 |
| BMI (kg/m2) | 29.0 ± 5.3 | 28.9 ± 5.3 | 29.2 ± 5.4 | .152 |
| Exercise Capacity (MET) | 8.24 ± 3.4 | 8.16 ± 3.5 | 8.82 ± 3.3 | <.001 |
| Risk Factors | ||||
| History of CVD | 1409 (24.2%) | 1270 (25.0%) | 139 (18.5%) | .001 |
| History of Hypertension | 3133 (53.8%) | 2756 (54.2%) | 377 (50.3%) | .041 |
| History of Dyslipidemia | 2194 (37.7%) | 1904 (37.5%) | 290 (38.7%) | .545 |
| History of Drugs | 135 (2.3%) | 109 (2.1%) | 26 (3.5%) | .036 |
| History of Alcohol Abuse | 228 (3.9%) | 194 (3.8%) | 34 (4.5%) | .363 |
| History of Diabetes | 955 (16.4%) | 837 (16.5%) | 118 (15.7%) | .635 |
| Current Smoking | 1438 (24.7%) | 1189 (23.4%) | 249 (33.2%) | <.001 |
| Physical Inactive | 2595 (44.5%) | 2275 (44.8%) | 320 (42.7%) | .271 |
| Medication | ||||
| Beta-blocker | 1287(22.1%) | 1143 (22.5%) | 144 (19.2%) | .043 |
| ACE Inhibitor | 1380 (23.7%) | 1215 (23.9%) | 165 (22%) | .250 |
| Antihypertensive | 954 (16.4%) | 859 (16.9%) | 95 (12.7%) | .003 |
| Diuretics | 397 (6.8%) | 350 (6.9%) | 47 (6.3%) | .587 |
| Statins | 819 (14.1%) | 730 (14.4%) | 89 (11.6%) | .072 |
BMI: Body Mass Index, MET: metabolic equivalent, CI: confidence interval, ACE: Angiotensin-converting enzyme, CVD: Cardiovascular disease
*comparing patients with cognitive impairment to those without by a Student’s t-test or chi2 if appropriate